MetaStat Demonstrates MenaCalc Lung™ Is Prognostic for Outcome in Non-Small Cell Lung Cancer

Data Presented Today at Annual Meeting of American Association for Cancer Research

Support Usefulness of MenaCalc™ as Prognostic Test for Predicting Outcome Beyond Early-Stage Breast Cancer to Include Squamous Cell Carcinoma of Lung

PHILADELPHIA--()--MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, today presented the positive results of a clinical study demonstrating the MenaCalc Lung™ score is an independent prognostic factor and predictive for distant metastasis in patients with non-small cell lung cancer at the annual meeting of the American Association for Cancer Research (AACR) in Philadelphia. The MenaCalc Lung™ test is a quantitative immunofluorescence diagnostic that measures the relative expression of different isoforms of the key pro-metastatic factor Mena, which quantifies the likelihood of the development of distant metastatic disease.

“This study demonstrates the benefit of the MenaCalc Lung™ assay in providing information to help physicians to better understand the metastatic potential of tumors in patients with squamous cell carcinoma,” said Oscar Bronsther, Chief Executive Officer and Chief Medical Officer of MetaStat. “Moreover, these data combined with earlier data in node-negative and node-positive patients with breast cancer show the breadth of our MenaCalc™ platform which we believe is applicable to all epithelial-derived tumors including non-small cell lung cancer and breast cancer.”

The study evaluated 201 patients with non-small cell lung cancer and demonstrated MenaCalc Lung™ scores were significantly (p=0.001) higher in patients with squamous cell carcinoma (N=32) as compared to other subtypes. High MenaCalc Lung™ scores were associated (10% significance level) with decreased five-year disease specific survival in all patients [HR=1.78 (95%CI: 0.92-3.43); P=0.08], and were significantly associated with survival in the squamous-only population [HR = 6.60 (95%CI: 1.22-53.75); P=0.04]. The study also demonstrated a two-fold increase (P=0.09) in MenaCalc scores in patients with metastatic disease (N=9). Furthermore, the MenaCalc score was independent of the classical clinicopathologic features such as stage, sex or age for predicting outcome.

The study was presented as a poster titled “MenaCalc as an Independent Prognostic Factor and Predictor of Metastasis in Non-Small Cell Lung Cancer” (Abstract P4331).

About MetaStat, Inc.

MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company’s function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat’s testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

Contacts

Media:
Dian Griesel Int’l. for MetaStat
Susan Forman, 212-825-3210
sforman@dgicomm.com
or
Investors:
MetaStat, Inc.
Rick Pierce, 617-714-5125
Rpierce@metastat.com

Release Summary

MetaStat presented the positive results of a clinical study at the AACR demonstrating the MenaCalc Lung is prognostic for outcome in non-small cell lung cancer.

Contacts

Media:
Dian Griesel Int’l. for MetaStat
Susan Forman, 212-825-3210
sforman@dgicomm.com
or
Investors:
MetaStat, Inc.
Rick Pierce, 617-714-5125
Rpierce@metastat.com